CE Disclosures and Faculty Information

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals.
  
  OVERVIEW OF ACTIVITY
  Clinical controversies and uncertainties persist in the management of all common cancers, and thousands of ongoing research trials worldwide attempt to provide new answers to long-standing clinical questions. As these trials reach maturity, clinical investigators initially present new data in abridged format at large scientific conferences and subsequently in full data sets formally published as part of peer-reviewed journals. Today, numerous annual oncology conferences release new clinical data and hundreds of peer-reviewed publications feature articles related to cancer research, treatment and practical management. The extensive list of available treatment options poses a challenge to the practicing clinician who must maintain knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.
  
  These proceedings from a daylong symposium combine the perspectives of 15 renowned investigators with a review of key recent presentations and publications across breast cancer, gastrointestinal cancers, genitourinary cancers, multiple myeloma, non-small cell lung cancer and Hodgkin and non-Hodgkin lymphoma, including chronic lymphocytic leukemia, to assist medical oncologists and hematologists in the formulation of up-to-date clinical management strategies.
  
  LEARNING OBJECTIVES
  

  • Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, gastrointestinal, genitourinary, dermatologic and select hematologic cancers.
  • Compare and contrast the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
  • Recall ongoing trials in breast, lung, gastrointestinal, genitourinary, dermatologic and select hematologic cancers, and refer appropriate patients for study participation.
  • Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
  • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
  • Refine or validate existing cancer-specific treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.

  ACCREDITATION STATEMENT
  
  CME credit is no longer available for this issue
  
  CREDIT DESIGNATION STATEMENT
  
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component. The participant should watch the video.
  
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — Drs Spigel and Yardley have no real or apparant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Mark D Pegram, MD
  Susy Yuan-Huey Hung Professor of Medicine
  Director of the Breast Oncology Program
  Co-Director, Translational Oncology Program
  Associate Director for Clinical Research
  Stanford Cancer Institute
  Stanford University School of Medicine
  Stanford, California
  
  Consulting Agreements: Celgene Corporation, Cepheid, Genentech BioOncology, Shionogi Inc.
  
  Denise A Yardley, MD
  Senior Investigator, Breast Cancer Research
  Sarah Cannon Research Institute
  Tennessee Oncology, PLLC
  Nashville, Tennessee
  
  No financial interests or affiliations to disclose.
  
  Omid Hamid, MD
  Chief of Research/Immuno-Oncology
  Director of Melanoma Program
  The Angeles Clinic and Research Institute
  Los Angeles, California
  
  Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Merck; Consulting Agreements: Bristol-Myers Squibb Company, Genentech BioOncology, Merck, Pfizer Inc; Contracted Research: Abbott Laboratories, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, GlaxoSmithKline, Lilly, MedImmune Inc, Merck, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Takeda Oncology; Speakers Bureau: Bristol-Myers Squibb Company, Genentech BioOncology.
  
  David F McDermott, MD
  Associate Professor of Medicine
  Harvard Medical School
  Director, Biologic Therapy and Cutaneous Oncology Programs
  Beth Israel Deaconess Medical Center
  Leader, Kidney Cancer Program
  Dana-Farber Harvard Cancer Center
  Boston, Massachusetts
  
  Advisory Committee: Pfizer Inc; Consulting Agreements: Bristol-Myers Squibb Company, Genentech BioOncology, Merck, Roche Laboratories Inc; Contracted Research: Novartis Pharmaceuticals Corporation.
  
  Charles S Fuchs, MD, MPH
  Director, Center for Gastrointestinal Cancer
  Dana-Farber/Harvard Cancer Center
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee: Acceleron Pharma, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly, Metamark Genetics Inc, Pfizer Inc, POZEN Inc, Sanofi, Takeda Oncology; Consulting Agreements: Acceleron Pharma, Celgene Corporation, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly, Metamark Genetics Inc, Pfizer Inc, POZEN Inc, Roche Laboratories Inc, Sanofi, Takeda Oncology.
  
  J Randolph Hecht, MD
  Professor of Clinical Medicine
  Carol and Saul Rosenzweig Chair in Cancer Therapies Development
  Director, UCLA GI Oncology Program
  Santa Monica, California
  
  Advisory Committee: Amgen Inc, Genentech BioOncology, Sanofi.
  
  Irene M Ghobrial, MD
  Assistant Professor in Medicine
  Dana-Farber Cancer Institute
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Genzyme Corporation, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology.
  
  Joseph Mikhael, MD, MEd
  Associate Dean, Mayo School of Graduate Medical Education
  Deputy Director - Education, Mayo Clinic Cancer Center
  Associate Professor, Mayo College of Medicine
  Mayo Clinic in Arizona
  Scottsdale, Arizona
  
  Contracted Research: Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Sanofi.
  
  David R Spigel, MD
  Program Director, Lung Cancer Research
  Sarah Cannon Research Institute
  Nashville, Tennessee
  
  No financial interests or affiliations to disclose.
  
  Heather Wakelee, MD
  Associate Professor of Medicine
  Division of Oncology
  Stanford University School of Medicine
  Stanford Cancer Institute
  Stanford, California
  
  Consulting Agreements: Peregrine Pharmaceuticals Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Exelixis Inc, Genentech BioOncology, Lilly, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Xcovery.
  
  Daniel P Petrylak, MD
  Professor of Medicine
  Director, Prostate and GU Medical Oncology
  Co-Director, Signal Transduction Program
  Yale Cancer Center
  New Haven, Connecticut
  
  Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Dendreon Corporation, Ferring, Johnson & Johnson Pharmaceuticals, Medivation Inc, Pfizer Inc, Sanofi, Takeda Oncology; Contracted Research: Celgene Corporation, Sanofi, Takeda Oncology; Grant Support: Dendreon Corporation, Johnson & Johnson Pharmaceuticals, OncoGenex Pharmaceuticals Inc, Progenics Pharmaceuticals Inc.
  
  Myron S Czuczman, MD
  Chief, Lymphoma/Myeloma Service
  Head, Lymphoma Translational Research Laboratory
  Roswell Park Cancer Institute
  Professor of Medicine
  School of Medicine and Biomedical Sciences
  State University of New York at Buffalo
  Buffalo, New York
  
  Advisory Committee: Algeta ASA, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Gilead Sciences Inc, Mundipharma International Limited, Teva Oncology.
  
  Ian W Flinn, MD, PhD
  Director of Blood Cancer Research
  Sarah Cannon Research Institute
  Tennessee Oncology
  Nashville, Tennessee
  
  Contracted Research: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Takeda Oncology.
  
  Christopher Flowers, MD, MS
  Associate Professor of Hematology and Medical Oncology
  Emory School of Medicine Winship Cancer Institute
  Atlanta, Georgia
  
  Advisory Committee: Biogen Idec, Genentech BioOncology, Roche Laboratories Inc; Consulting Agreements: Algeta ASA, Celgene Corporation, OptumRx Inc; Contracted Research: Abbott Laboratories, Celgene Corporation, Spectrum Pharmaceuticals Inc, Takeda Oncology.
  
  Craig Moskowitz, MD
  Clinical Director, Division of Hematologic Oncology
  Attending Physician, Lymphoma and Adult BMT Services
  Member, Memorial Sloan Kettering Cancer Center
  Professor of Medicine, Weill Medical College of Cornell University
  New York, New York
  
  Advisory Committee: Genentech BioOncology, Seattle Genetics; Contracted Research: Genentech BioOncology, GlaxoSmithKline, Merck, Seattle Genetics.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.
  
  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas Scientific and Medical Affairs Inc, Bayer HealthCare Pharmaceuticals, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Genentech BioOncology, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Sanofi, Seattle Genetics and Takeda Oncology.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
  Adobe Flash Player 10.2 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Last review date: February 2015
  Expiration date: February 2016